XML 49 R27.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Liquidity (Details) - USD ($)
3 Months Ended 6 Months Ended
Jan. 25, 2020
Jan. 21, 2020
Dec. 16, 2019
Dec. 07, 2019
Nov. 01, 2019
Dec. 31, 2019
Sep. 30, 2019
Dec. 31, 2018
Sep. 30, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 26, 2019
Jun. 30, 2019
Financial Condition [Line Items]                          
Retained Earnings (Accumulated Deficit)           $ (95,605,245)       $ (95,605,245)     $ (92,116,586)
Net loss           (1,927,526) $ (1,561,133) $ (2,230,992) $ (1,841,463) (3,488,659) $ (4,072,455)    
Net Cash Provided by (Used in) Operating Activities                   (2,560,245) (3,120,563)    
Revenue                   0 $ 0    
Cash and cash equivalents           $ 707,648       $ 707,648     $ 2,555,207
Common Stock, Par or Stated Value Per Share           $ 0.001       $ 0.001     $ 0.001
Common stock, par value (in dollars per share)           0.001       0.001     $ 0.001
Underwriters option to purchase additional shares (in shares)   375,000                      
Over Allotment Option | Subsequent event                          
Financial Condition [Line Items]                          
Common Stock, Par or Stated Value Per Share   $ 0.001                      
Common stock, shares issued and sold (in shares)   2,500,000                      
Common stock, par value (in dollars per share)   $ 0.001                      
Public offering price (in dollars per share) $ 3.00 $ 3.00                      
Underwriters option to purchase additional shares (in shares) 375,000 375,000                      
Period to avail over-allotment option   45 days                      
Underwriter's commission and agreed upon customary fees and expenses $ 7,780,000 $ 7,800,000                      
Maximum [Member] | Series A Preferred stock                          
Financial Condition [Line Items]                          
Public offering price (in dollars per share)           $ 2.60       $ 2.60      
TheraCour                          
Financial Condition [Line Items]                          
Common stock, shares issued and sold (in shares)         75,000                
TheraCour | Series A Preferred stock                          
Financial Condition [Line Items]                          
Deferred development fees exchanged for shares       $ 250,000                  
Series A shares issued in exchange of deferred development fees owed (in shares)     10,000 100,000                  
Open End Mortgage Note | Anil Diwan                          
Financial Condition [Line Items]                          
Drew down amount           $ 1,100,000       $ 1,100,000      
Open End Mortgage Note | Anil Diwan | Maximum [Member]                          
Financial Condition [Line Items]                          
Amount of loan     $ 2,000,000                 $ 2,000,000